Published
9 months agoon
Healios has created ‘universal donor cells’ (UDCs) using gene-editing technology that allows them to reduce the body’s immune rejection response.
The development will allow for the creation of regenerative pharmaceutical products with a lower risk of immune rejection, while preserving the inherent ability of the cells to replicate themselves continuously.
UDCs are induced pluripotent stem cells created using gene-editing technology that allows them to reduce the body’s immune rejection response.
Their production involves the removal of certain genes that elicit a rejection response, the introduction of an immunosuppression gene to improve immune evasion, and the addition of a suicide gene serving as a safety mechanism.
Healios plans to combine its UDC technology with its existing efforts in next-generation cancer-targeting immune cells to create a line of regenerative medicine therapies with the highest possible safety and efficacy profile.
Typically, transplanted cells trigger an immune rejection response in patients whose human leukocyte antigen (HLA) type does not match that of the cells.
HLA is an important molecule expressed in all human cells that is involved in how the immune system functions.
Any substance in an individual’s body with an HLA type that differs from the individual’s own is recognised as a foreign substance, which triggers an immune response that rejects and attacks that substance. Therefore, ensuring a match of HLA types is extremely important in organ transplantation.
Therefore, doctors must administer an immunosuppressant drug during transplantation, which increases the burden on the patient’s body.
To avoid the administration of immunosuppressants, it is preferable to utilise autologous iPS cells produced by the patient’s own cells, but the production process both takes a long time and is very expensive.
Healios pioneers regenerative medicines in Japan, using gene-modified stem cells (iPSCs) to develop regenerative treatments in immune-oncology cell therapies targeting solid tumors and liver diseases, and ophthalmology.
It was established in 2011 and to date has raised over US$330 million in funds to support its growth and development.
The Company has been listed on the Tokyo Stock Exchange since 2015.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.